NasdaqCM - Delayed Quote USD

Precipio, Inc. (PRPO)

Compare
6.00 -0.01 (-0.08%)
At close: November 21 at 4:00 PM EST
Loading Chart for PRPO
DELL
  • Previous Close 6.01
  • Open 6.00
  • Bid 5.16 x 100
  • Ask 6.88 x 100
  • Day's Range 5.98 - 6.00
  • 52 Week Range 4.31 - 7.30
  • Volume 2,080
  • Avg. Volume 8,470
  • Market Cap (intraday) 8.894M
  • Beta (5Y Monthly) 1.42
  • PE Ratio (TTM) --
  • EPS (TTM) -1.81
  • Earnings Date Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.

www.precipiodx.com

51

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PRPO

View More

Performance Overview: PRPO

Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PRPO
7.69%
S&P 500
24.72%

1-Year Return

PRPO
15.85%
S&P 500
30.82%

3-Year Return

PRPO
84.69%
S&P 500
26.62%

5-Year Return

PRPO
85.00%
S&P 500
91.37%

Compare To: PRPO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PRPO

View More

Valuation Measures

Annual
As of 11/20/2024
  • Market Cap

    8.89M

  • Enterprise Value

    9.12M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.50

  • Price/Book (mrq)

    0.74

  • Enterprise Value/Revenue

    0.52

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -22.90%

  • Return on Assets (ttm)

    -18.98%

  • Return on Equity (ttm)

    -29.22%

  • Revenue (ttm)

    16.72M

  • Net Income Avi to Common (ttm)

    -3.83M

  • Diluted EPS (ttm)

    -1.81

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.28M

  • Total Debt/Equity (mrq)

    9.66%

  • Levered Free Cash Flow (ttm)

    -894.75k

Research Analysis: PRPO

View More

Company Insights: PRPO

Research Reports: PRPO

View More

People Also Watch